ONK opens US operations and becomes a resident of Johnson & Johnson Innovation JLABS @ San Diego Rohit Duggal Ph.D. appointed as Head of R&D, USA ONK Therapeutics, Inc. formed, to facilitate the expansion of operations in the USA, alongside its growing hub in Galway, Ireland Galway, Ireland and San Diego, USA, 12 November 2020 […]
This author has yet to write their bio.
Meanwhile lets just say that we are proud nacnkcell contributed a whooping 9 entries.
Labiotech – View full story
Fierce Biotech – View full story
Endpoints – View full story
Off-the-shelf natural killer cell therapy company, targeting solid and hematological cancers Raises US$8M from US-based investor Acorn Bioventures and current shareholders, bringing total raised in last six months to US$14.6M Funding will enable expansion of R&D and manufacturing capabilities, and progression of its two lead programs towards the clinic: ONKT101 a dual-targeted NK cell therapy […]
Avectas announced that it has exclusively licenced from ONK Therapeutics (ONK) a Chimeric Antigen Receptor-directed Natural Killer (CAR NK) cell therapy incorporating ONK’s proprietary Death Receptor (DR5) TRAIL variant for the treatment of B-cell malignancies. Under the collaboration, ONK will be responsible for rapidly progressing the potential therapy to a Phase I clinical trial. The […]
Today, The Department for Business, Enterprise and Innovation through the Disruptive Technologies Innovation Fund announced that Galway based ONK Therapeutics Ltd, together with it’s consortium partners Janssen Sciences Ireland UC based in Cork and the Centre for Cell Manufacturing Ireland based at NUI Galway, are one of it’s 27 chosen projects to receive funding in […]